Patents by Inventor Andreas Bültmann

Andreas Bültmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11472880
    Abstract: The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: October 18, 2022
    Assignee: MORPHOSYS AG
    Inventors: Thomas Tiller, Steffen Runz, Julia Neugebauer, Andreas Bültmann
  • Publication number: 20220041719
    Abstract: Novel antigen-binding molecules are provided, with the ability to target different antigens with different valency, e.g. one antigen monovalently and another antigen bivalently.
    Type: Application
    Filed: December 4, 2019
    Publication date: February 10, 2022
    Inventors: Andreas Bültmann, Karin Felderer, Sebastian Jäger, Steffen Runz, Johannes Urban
  • Patent number: 11085038
    Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: August 10, 2021
    Assignee: MORPHOSYS AG
    Inventors: Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
  • Publication number: 20200377594
    Abstract: The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
    Type: Application
    Filed: August 13, 2018
    Publication date: December 3, 2020
    Inventors: Thomas TILLER, Steffen RUNZ, Julia NEUGEBAUER, Andreas BÜLTMANN
  • Patent number: 10815297
    Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 27, 2020
    Assignees: MORPHOSYS AG, GALAPAGOS NV
    Inventors: Andreas Bültmann, Robert Mühlbacher, Teresa Garcia, Reginald Christophe Xavier Brys, Luc Nelles, Katja Conrath
  • Publication number: 20200231963
    Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 23, 2020
    Inventors: Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
  • Patent number: 10655125
    Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 19, 2020
    Assignee: MOR0059US.NP
    Inventors: Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
  • Publication number: 20190270981
    Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 5, 2019
    Inventors: Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
  • Publication number: 20190062422
    Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.
    Type: Application
    Filed: November 8, 2018
    Publication date: February 28, 2019
    Inventors: Andreas BÜLTMANN, Robert MÜHLBACHER, Teresa GARCIA, Reginald Christophe Xavier BRYS, Luc NELLES, Katja CONRATH
  • Publication number: 20160060347
    Abstract: This disclosure generally relates to antibodies or fragments thereof which interact with CXCR2. The disclosure further discloses antibodies, which bind to specific extracellular domains of CXCR2. The disclosure further relates to therapeutics comprising CXCR2-specific antibodies and methods of treatment using CXCR2-specific antibodies or fragments thereof.
    Type: Application
    Filed: April 15, 2014
    Publication date: March 3, 2016
    Inventors: Tanja Herrmann, Andreas Bueltmann
  • Publication number: 20140243506
    Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.
    Type: Application
    Filed: October 19, 2012
    Publication date: August 28, 2014
    Inventors: Andreas Bültmann, Robert Mühlbacher, Teresa Garcia, Reginald Christophe Xavier Brys, Luc Nelles, Katja Conrath
  • Publication number: 20130130315
    Abstract: An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x.
    Type: Application
    Filed: April 6, 2011
    Publication date: May 23, 2013
    Applicant: ADVANCECOR GMBH
    Inventors: Meinrad Gawaz, Tanja Schönberger, Heidrun Degen, Götz Münch, Hans-Peter Holthoff, Andreas Bültmann, Hans-Jörg Bühring, Christoph Leder
  • Patent number: 8119135
    Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: February 21, 2012
    Assignees: Helmhotz Zentrum Munchen, Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH), Corimmun GmbH
    Inventors: Götz Münch, Meinrad Gawaz, Andreas Bültmann, Elisabeth Kremmer
  • Patent number: 7531178
    Abstract: The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterized by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: May 12, 2009
    Assignee: Trigen GmbH
    Inventors: Steffen Massberg, Meinrad Gawaz, Andreas Bültmann, Götz Münch, Martin Ungerer, Mario Peluso
  • Patent number: 7514543
    Abstract: The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: April 7, 2009
    Assignee: Trigen GmbH
    Inventors: Steffen Massberg, Meinrad Gawaz, Andreas Bültmann, Götz Münch, Martin Ungerer, Mario Peluso
  • Patent number: 7169612
    Abstract: Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: January 30, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Evi Kostenis, Paulus Wohlfart, Jochen Huber, Kai Rosport, Andreas Bueltmann, Christine Baumgartner, Götz Muench, Martin Ungerer
  • Publication number: 20040132182
    Abstract: Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.
    Type: Application
    Filed: November 12, 2003
    Publication date: July 8, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Evi Kostenis, Paulus Wohlfart, Jochen Huber, Kai Rosport, Andreas Bueltmann, Christine Baumgartner, Gotz Muench, Martin Ungerer